Iodine and Prostate Health: A Scientific Review

Nearly all research connecting iodine to prostate health comes from laboratory and animal studies, with only a handful of human observations to draw on. The findings are genuinely intriguing: prostate cells can absorb iodine through specific transporters, and in cell culture, certain forms of iodine slow the growth of prostate cancer cells and reduce markers of inflammation. But the leap from petri dish to practical health advice has not been made, and the few epidemiological clues available paint a complicated, sometimes contradictory picture.

How the Prostate Takes Up Iodine

The thyroid gland is the organ most famously associated with iodine, but it is not the only tissue that absorbs it. The prostate gland expresses the sodium/iodide symporter (NIS), a protein that actively pumps iodide into cells. In a study of 78 prostate cancer specimens, NIS protein was detected in about half of the tumors, and its presence correlated with markers of more aggressive disease, including higher-stage tumors and higher Gleason scores. Interestingly, NIS was absent in nontumor hyperplastic tissue, suggesting that its expression may be switched on as part of the cancer process rather than being a normal feature of healthy prostate cells.¹

Iodine exists in two main chemical forms relevant here: iodide (I⁻, the ionic form) and molecular iodine (I₂). These appear to enter prostate cells by different routes. Work in a mouse model of prostate cancer showed that both normal and cancerous prostate tissue took up both forms, but only iodide uptake was blocked by perchlorate, a known NIS inhibitor. That finding implies a separate, still-unidentified transporter handles molecular iodine.² Cell-line experiments reinforced this picture: in noncancerous prostate cells, iodide uptake depended on NIS, whereas in two cancer cell lines (LNCaP and DU-145), it did not.³ The practical takeaway is that iodine can get into prostate cells through more than one door, and cancer cells may use a different entrance than normal cells do.

What Iodine Does Inside Prostate Cells

Once inside the cell, iodine is not just sitting around. One well-studied pathway involves the formation of iodolipids, particularly a compound called 6-iodolactone (6-IL). These iodine-containing lipids interact with a receptor family called PPARγ, which can trigger cells to stop dividing or to undergo programmed cell death (apoptosis).⁴ A separate, more direct mechanism has also been documented: oxidized iodine can disrupt the electrical charge across the mitochondrial membrane, which is a well-known trigger for the cell’s self-destruction sequence.⁵

In cell-culture experiments, both molecular iodine and 6-IL slowed proliferation in a dose- and time-dependent manner across noncancerous and cancerous prostate cell lines, though different cell types responded differently. Noncancerous cells were more sensitive to iodide, while one cancer cell line (LNCaP) responded more strongly to molecular iodine.³ More recent work has added nuance: when molecular iodine was combined with androgen deprivation (a standard prostate cancer strategy), the cytotoxic effects were amplified, and surviving cells showed reduced invasive capacity and neurite-like structural changes. A PPARγ blocker did not prevent these effects, suggesting that in prostate cancer cells, iodine may work through a PPARγ-independent route.⁶ That same PPARγ independence was confirmed in an androgen-deprivation context using bicalutamide and enzalutamide alongside molecular iodine.

These findings sketch out a picture of iodine acting on prostate cells through multiple channels at once. But it is worth emphasizing that all of this evidence comes from cells growing in dishes or from mice genetically engineered to develop prostate tumors. The doses and concentrations used in these experiments do not translate directly to anything a person would consume.

Iodine as an Antioxidant in Prostate Tissue

Oxidative stress plays a recognized role in the development of benign prostatic hyperplasia (BPH). When rats were given testosterone to induce prostatic overgrowth, supplemental molecular iodine prevented both the increase in prostate DNA content (a measure of cell proliferation) and the rise in oxidative stress markers. The effect was comparable to that of celecoxib, a COX-2 inhibitor used as a positive control. Mechanistically, iodine appeared to work by blocking nitric oxide synthase (NOS) and the COX-2 inflammatory pathway. In a cell-free test system, molecular iodine also directly inhibited the chemical conversion of nitrate to nitrite, confirming an intrinsic antioxidant capacity.⁷

One detail from that study is easy to overlook but important: iodine did not change the oxidative state of prostate tissue in rats that were not given testosterone. In other words, the antioxidant benefit appeared only when oxidative damage was actively being driven by excess hormone stimulation. This conditional effect hints that iodine might be useful under specific pathological conditions rather than as a blanket protective supplement.

Population-Level Evidence

The largest piece of human epidemiological data comes from a follow-up of participants in the first National Health and Nutrition Examination Survey (NHANES I). Researchers stratified men by their urinary iodine-to-creatinine ratio, a standard marker of iodine intake, and tracked prostate cancer diagnoses over subsequent years. The relationship was not straightforward: men with moderate iodine levels had a slightly elevated risk of prostate cancer compared to men with low levels, while men with the highest iodine levels had a roughly 30% lower risk. That U-shaped or J-shaped pattern suggests neither deficiency nor moderate intake is ideal, but very high intake might be protective.⁸

This finding loosely echoes a long-standing ecological observation: populations in Asia that consume large amounts of seaweed (a rich source of iodine in multiple chemical forms) have historically had lower rates of both benign and cancerous prostate disease. Iodine intake in these communities has been estimated at roughly 25 times higher than in Western countries.⁵ The problem with ecological comparisons like this is obvious: populations that eat a lot of seaweed also differ in dozens of other dietary and lifestyle factors, from soy consumption to physical activity levels. Iodine could be one piece of the puzzle, a bystander, or something in between. No randomized trial has tested whether iodine supplementation reduces prostate cancer risk in humans.

The Thyroid Hormone Complication

Iodine’s most established biological role is as the raw material for thyroid hormones, and the thyroid-prostate connection adds a layer of complexity to the whole question. If iodine influences prostate health, is it acting directly on prostate cells, or is it doing so indirectly by changing thyroid hormone levels? The answer may be both, and the indirect route is surprisingly tangled.

A Mendelian randomization study (which uses genetic variants as proxies for exposure) found that genetically predicted hyperthyroidism was associated with a lower risk of prostate cancer, with an odds ratio of about 0.86.⁹ That would suggest higher thyroid activity is protective. But a separate study measuring actual blood hormone levels found the opposite pattern: men with the highest thyroid-stimulating hormone (TSH) levels, which usually indicates an underactive thyroid, had about a 30% lower risk of prostate cancer. Men classified as hypothyroid in that study also showed reduced risk compared to those with normal thyroid function.¹⁰

A 2025 systematic review and meta-analysis attempted to settle this by pooling available evidence. The result was largely a wash: thyroid abnormalities overall showed no statistically significant association with prostate cancer risk. When broken down, hyperthyroidism had a hazard ratio of 1.64, but the confidence interval just barely touched 1.0, meaning the result was borderline at best. Hypothyroidism showed a nonsignificant trend toward lower risk.¹¹

At the cellular level, the story gets messier. Thyroid hormone receptor beta (TRβ) is present in prostate cancer cells, and treatment with the active thyroid hormone T3 stimulated proliferation in certain cell lines, including a castration-resistant model.¹² However, earlier work showed that T3 only boosted growth in one of five prostate cell lines tested (LNCaP), with no effect on others. In some cell types, the thyroid receptor was present but located on the nuclear membrane rather than inside the nucleus, which may explain why it failed to relay growth signals.¹³

What all of this means for someone thinking about iodine is that you cannot simply reason backward from “iodine supports thyroid function, and thyroid hormones affect the prostate, so iodine must help the prostate.” The relationship between thyroid status and prostate cancer risk is genuinely unclear at the population level, and the cellular effects of thyroid hormones on prostate cells depend heavily on the specific cell type.

What Animal Studies Actually Show

Given the promising cell-culture results, you might expect animal studies to show clear protective effects. The reality is more sobering. In TRAMP mice, a genetically engineered model that spontaneously develops prostate cancer, supplementation with a combination of iodide and molecular iodine for up to 24 weeks did not prevent cancer progression. Iodine did increase expression of the tumor-suppressor gene p53, but this did not translate into measurable effects on tumor weight, cell proliferation, or apoptosis.² That gap between what happens in isolated cells and what happens in a living animal is a consistent theme in cancer research, and it tempers the enthusiasm generated by the cell-line data.

The picture looks somewhat better for benign prostatic hyperplasia. In rat models of BPH, iodine bonded with milk protein (called ISMP) significantly reduced prostate weight and the prostatic index. The effect was not as strong as finasteride, a standard BPH drug, but histological analysis showed fewer signs of hyperplasia in iodine-treated animals.¹⁴ When ISMP was combined with lycopene, the two produced an additive benefit, reducing prostate weight further than either compound alone.¹⁵ These are encouraging rat results, but no human trial has tested iodine supplementation for BPH prevention or treatment.

Radioactive Iodine in Prostate Cancer Treatment

A completely different strand of prostate-iodine research involves radioactive isotopes of iodine used not as nutrients but as weapons against tumors. These applications exploit the physics of radioactive decay rather than any biochemical property of iodine, so they are a separate topic from dietary iodine, though they are often grouped together in discussions of “iodine and the prostate.”

Iodine-125 seed brachytherapy is an established treatment for localized prostate cancer. Small radioactive seeds are implanted directly into the prostate, delivering continuous low-dose radiation to the tumor while sparing surrounding tissue. In a multi-institutional Japanese study of low-risk and intermediate-risk patients, the seven-year biochemical failure-free survival rate was above 95%, and cancer-specific survival reached 99%.¹⁶ A Brazilian single-institution cohort followed for a median of about seven years reported ten-year overall survival of 85% and metastasis-free survival of 94%, with manageable side effects: serious urinary toxicity was uncommon, and severe gastrointestinal complications occurred in fewer than 1% of patients.¹⁷ For higher-risk patients, combining I-125 seeds with external beam radiation has also shown strong results, with a ten-year cancer-specific survival of 99% in one series.¹⁸

Brachytherapy is well established, but researchers have also explored more experimental approaches. Gene therapy strategies aim to force prostate cancer cells to express NIS at high levels, essentially turning the tumor into a thyroid-like iodine sponge that can then be targeted with therapeutic doses of radioactive iodine-131. In a mouse experiment, injecting an adenovirus carrying the NIS gene into prostate tumor grafts led to strong radioiodine uptake, and subsequent treatment with iodine-131 reduced tumor volume by an average of 84%.¹⁹ Refinements have included linking NIS expression to prostate-specific promoters so that only prostate cells, not bystander tissues, take up the radioiodine. One such approach used the PSMA promoter to drive NIS expression, achieving prostate-specific targeting and effective radioiodine therapy in a castration-resistant prostate cancer model.²⁰ Another group developed a replication-competent adenovirus that simultaneously expressed a therapeutic suicide gene and NIS, using the NIS component as a built-in imaging tool to monitor where the virus went and how much gene expression it achieved.²¹

These gene therapy strategies remain experimental and have not reached human clinical use for prostate cancer. But they illustrate how the basic biology of iodine transport has been repurposed: if you can get tumor cells to absorb enough radioactive iodine, you can destroy them from the inside, borrowing the same principle that has made radioiodine therapy highly effective against thyroid cancer for decades.

Why Supplements Are Not the Takeaway

Given all of this research, you might wonder whether taking iodine supplements could benefit your prostate. The honest state of the evidence does not support that conclusion. The cell-culture effects require concentrations far above what dietary iodine achieves in prostate tissue. The most relevant animal study, using a well-validated genetic model of prostate cancer, found no benefit from iodine supplementation on tumor progression.² The single epidemiological study in humans showed a nonlinear relationship where only very high iodine levels were associated with lower risk, and ecological comparisons between countries are riddled with confounders.⁸

There is also the question of safety. Excess iodine intake can cause thyroid dysfunction, including both hyper- and hypothyroidism, particularly in people with preexisting thyroid conditions. Since the relationship between thyroid hormones and prostate cancer is itself unresolved, pushing iodine intake to high levels could have unpredictable downstream effects. The tolerable upper intake level set by most health authorities is 1,100 micrograms per day for adults, well below the levels consumed in some seaweed-heavy diets. Exceeding that threshold without medical supervision is not a sensible gamble based on the current evidence.

Where the research stands is a familiar position in cancer biology: there is a plausible mechanism, some encouraging cell and animal data for benign conditions, and a near-total absence of human clinical trials testing whether any of it translates. The most advanced clinical application of iodine in prostate care remains radioactive seed brachytherapy, where the element is used as a radiation vehicle, not a nutrient. If future work produces a human trial showing that a specific form of iodine at a defined dose reduces BPH progression or prostate cancer risk, the conversation will change. Until then, the laboratory findings are worth watching but not worth acting on with a supplement bottle.